Ketamine appears in two different public conversations: rising concern about harmful use and interest in depression treatment. Combining them creates confusion. Medical use does not make unsupervised use safe, and evidence of harm does not settle the value of a specific medical intervention. For families choosing private care, the product, purpose, and treatment setting matter.
Key findings
5,365: adults starting substance-use treatment with ketamine problems in England in 2024/25, compared with 426 in 2014/15.
3.2%: the share of new entrants reporting ketamine problems in 2024/25, compared with 2.3% the previous year.
Nearly 41%: the increase in ketamine residues in EUDA’s comparable-city analysis of 2024 and 2025.
40 increased, 14 were stable, and 12 decreased: the breakdown among 66 cities in that comparison.
Treatment entries and wastewater observations answer different questions. Neither identifies the number of wealthy people using ketamine or measures treatment success. [1] [2]
The treatment-entry signal is substantial
The count increased more than twelvefold over the decade. Changes in need, recognition, and access may all affect treatment entries; the chart does not isolate their contributions. Source: England’s adult substance-misuse treatment report. [1]
The important distinction is between people entering covered services and everyone experiencing a problem. An entry count cannot establish population prevalence. It also cannot show whether people seeking care through private services have the same profile as those represented in the report.
Wastewater adds another kind of evidence
England’s separate WAND analysis recorded a rising ketamine consumption estimate at 16 consistently sampled catchments. Its January to April point estimate increased from 324 milligrams per 1,000 people per day in 2021 to 1,066 in 2025. These are modeled catchment estimates, not England-wide totals or counts of individual users. [3]
| January to April period | mg per 1,000 people per day | Published interval, plus/minus |
|---|---|---|
| 2021 | 324 | 8 |
| 2022 | 353 | 5 |
| 2023 | 391 | 15 |
| 2024 | 691 | 34 |
| 2025 | 1,066 | 30 |
Source: Home Office WAND, revised June 2026 Table 2. The source’s interval notation is retained. [3]
The later point estimates rose more sharply. This does not identify how many people used ketamine or how many had a use disorder. Source: Home Office WAND. [3]
The English and European monitoring programs use different methods and coverage. Their results can motivate questions about changing exposure and service readiness, but should not be combined into one percentage. The European release appeared in March 2026 and described 2025 sampling, not use during the publication month.
The medical story must name the product
In a June 23, 2026 warning letter, the FDA distinguished ketamine approved as an anesthetic from esketamine nasal spray approved for specified depressive indications under restricted supervision. It reiterated that ketamine itself is not FDA-approved for a psychiatric disorder. The product, indication, route, and setting are part of the claim. [4]
This does not make every off-label clinical use automatically unlawful or ineffective. It means that approval or evidence for one formulation cannot become a blanket endorsement of another. Patients should know exactly what is proposed and which evidence supports it.
A US regulatory statement is also not a worldwide authorization. An internationally mobile patient needs an explanation of the clinical responsibilities and requirements where treatment will occur. The reputation of a destination or provider cannot substitute for that information.
Medical use is not a general safety guarantee
The fact that a substance has legitimate medical uses does not establish the safety of unsupervised exposure. Clinical indication, formulation, monitoring, other substances, and the person’s health all affect the context. A reference to hospital use leaves those questions unanswered.
The FDA warning discusses risks associated with unapproved products and insufficient supervision. Separately, NHS services have developed specialist care for young people with ketamine-related urinary complications. These are different clinical settings, but both require attention to the actual exposure and problem rather than the drug name alone. [4] [5]
Persistent pain, urinary difficulties, or blood in the urine warrant prompt medical assessment. Severe or rapidly worsening symptoms require urgent care. A psychological treatment plan should not be presented as a replacement for specialist evaluation when physical symptoms need attention.
Two clinical questions need different outcomes
| Context | Relevant measures | Misleading shortcut |
|---|---|---|
| Treatment for harmful use | Use, symptoms, physical health, functioning, and follow-up | Calling a brief period without use complete recovery |
| A depression intervention | Symptom change, remission, adverse effects, and durability | Borrowing results from another product or indication |
| Population monitoring | Exposure, service demand, and harms | Calling a residue increase diagnosed addiction |
A positive depression trial does not establish the effectiveness of a program for harmful ketamine use. A decline in wastewater residues would not establish better treatment outcomes either. Each result must remain attached to the question it was designed to answer.
For rapid-acting interventions, the next question is how long the observed benefit lasts and what continuing treatment is required. Early symptom improvement is valuable information, but not evidence of a permanent result or a reason to abandon the wider care plan.
Why this matters for affluent families
Access to many private interventions can coexist with uncertainty about their evidence. A service marketed as innovative should explain the studied population, expected benefit, known risks, and follow-up. Novelty is not itself an outcome, and a premium setting does not remove the need to discuss uncertainty.
The same standard applies when a family seeks help for harmful use. The program should explain how physical complications and mental health needs will be assessed together, which clinicians are responsible, and where additional expertise is needed.
For patients using care across countries, clarify who holds the treatment history and who responds after travel or discharge. A suggested handover is not the same as an agreed arrangement. These are care-planning questions, not measured rates of failure among wealthy or international patients.
Questions to ask before committing to treatment
Begin with the indication and proposed intervention. Which difficulty is being treated? What exact product, route, or program is involved? Which evidence applies to this patient’s circumstances? A clear answer should separate established findings from expectations that remain uncertain.
Next, examine the review plan. What will be measured before treatment and afterward? Which adverse effects are monitored? What happens if the expected benefit does not occur? A positive short-term assessment should not replace a plan for reassessment and continuing support.
Finally, ask about the people missing from the outcome report. How many started, completed, and responded at each follow-up? Results among respondents do not automatically describe everyone treated. Missing information should be visible without assuming that all missing patients recovered or all failed.
A provider should also distinguish evidence for one treatment component from evidence for the complete package. Combining several interventions does not make the strongest study of one component a validation of everything offered. The comparison should focus on the actual clinical plan.
Keep the two stories separate in media coverage
A report about rising harmful use should not borrow the language of a depression-treatment trial to imply that unsupervised exposure is therapeutic. A report about a supervised intervention should not use population monitoring as proof of its effectiveness or safety. Naming the precise question helps readers understand why two apparently conflicting stories can coexist.
The comparison is most useful when it leads to a practical question about services. Are physical complications and mental health needs assessed together? Can patients understand which treatment is being proposed? Is follow-up defined beyond an initial response? The existing figures motivate those questions without supplying an answer about every clinic or patient.
What these numbers cannot tell us
None of the sources estimates ketamine use among high-net-worth families, executives, or founders. A city’s economic profile cannot identify individual users. The monitoring and treatment-entry figures do not measure depression-treatment effectiveness or the results of THE BALANCE.
The clinical and regulatory discussion concerns specified products and settings, not a recommendation to seek ketamine treatment. No original patient dataset, private-market survey, or pooled estimate across the monitoring programs was created.
The bottom line
The rise in ketamine-related treatment demand deserves attention. It does not settle the separate question of which medical interventions are appropriate for an individual. One drug name is not one evidence base. Families with choice should insist on a defined claim, relevant evidence, and clear responsibility for what happens next.
For journalists
Key comparison: 5,365 adults began covered treatment with ketamine problems in England in 2024/25, compared with 426 in 2014/15.
Important caveat: treatment entries, wastewater estimates, and medical approvals are separate measures.
Suggested attribution: THE BALANCE analysis of English treatment statistics, wastewater findings, and product-specific regulatory information.
Methodology and sources
The article preserves the original data periods and the revised English wastewater series. It does not pool monitoring results or infer the cause of increased treatment entries. Population findings, clinical interpretation, and regulatory statements remain separate.
- Office for Health Improvement and Disparities. Adult substance-misuse treatment statistics, 2024/25.
- EUDA/SCORE. Wastewater findings, March 2026.
- Home Office. Wastewater analysis, amended June 2026.
- FDA. Ketamine-product warning letter, June 23, 2026.
- NHS Cheshire and Merseyside. Specialist care for ketamine-related complications, July 2025.
